Abstract Nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) regulates the basal and stress-
inducible expression of a battery of genes encoding key components of the glutathione …

In order to maintain genomic stability, cells have developed sophisticated signalling
pathways to enable DNA damage or DNA replication stress to be resolved. Key mediators of …

There is substantial heterogeneity among primary prostate cancers, evident in the spectrum
of molecular abnormalities and its variable clinical course. As part of The Cancer Genome …

Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this …

Genetic screens are powerful tools for identifying genes responsible for diverse phenotypes.
Here we describe a genome-wide CRISPR/Cas9-mediated loss-of-function screen in tumor …

The molecular underpinnings that drive the heterogeneity of KRAS-mutant lung
adenocarcinoma are poorly characterized. We performed an integrative analysis of …

Focal amplification and activating point mutation of the MET gene are well-characterized
oncogenic drivers that confer susceptibility to targeted MET inhibitors. Recurrent somatic …

Small cell lung cancer (SCLC) is an aggressive disease that accounts for approximately
14% of all lung cancers. In the United States, approximately 31,000 patients are diagnosed …

Mutations in the MET exon 14 RNA splice acceptor and donor sites, which lead to exon
skipping, deletion of the juxtamembrane domain containing the CBL E3-ubiquitin ligase …

Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and
other diseases. Currently, more than 25 oncology drugs that target kinases have been …